ID   FGFR2-2_HUMAN           Reviewed;         768 AA.
AC   P21802-2;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   05-DEC-2018, entry version 241.
DE   RecName: Full=Isoform 2 of Fibroblast growth factor receptor 2;
DE            Short=FGFR-2;
DE            EC=2.7.10.1 {ECO:0000269|PubMed:16844695, ECO:0000269|PubMed:18056630, ECO:0000269|PubMed:19410646, ECO:0000269|PubMed:21454610};
DE   AltName: Full=K-sam;
DE            Short=KGFR;
DE   AltName: Full=Keratinocyte growth factor receptor;
DE   AltName: CD_antigen=CD332;
DE   Flags: Precursor;
GN   Name=FGFR2; Synonyms=BEK, KGFR, KSAM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Neonatal brain stem;
RX   PubMed=1697263;
RA   Dionne C.A., Crumley G.R., Bellot F., Kaplow J.M., Searfoss G.,
RA   Ruta M., Burgess W.H., Jaye M., Schlessinger J.;
RT   "Cloning and expression of two distinct high-affinity receptors cross-
RT   reacting with acidic and basic fibroblast growth factors.";
RL   EMBO J. 9:2685-2692(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 16).
RX   PubMed=2172978; DOI=10.1073/pnas.87.20.8180;
RA   Houssaint E., Blanquet P.R., Champion-Arnaud P., Gesnel M.-C.,
RA   Torriglia A., Courtois Y., Breathnach R.;
RT   "Related fibroblast growth factor receptor genes exist in the human
RT   genome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8180-8184(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 17).
RX   PubMed=1647213; DOI=10.1016/0167-4781(91)90015-E;
RA   Seno M., Sasada R., Watanabe T., Ishimaru K., Igarashi K.;
RT   "Two cDNAs encoding novel human FGF receptor.";
RL   Biochim. Biophys. Acta 1089:244-246(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4).
RC   TISSUE=Stomach cancer;
RX   PubMed=2377625; DOI=10.1073/pnas.87.15.5983;
RA   Hattori Y., Odagiri H., Nakatani H., Miyagawa K., Naito K.,
RA   Sakamoto H., Katoh O., Yoshida T., Sugimura T., Terada M.;
RT   "K-sam, an amplified gene in stomach cancer, is a member of the
RT   heparin-binding growth factor receptor genes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5983-5987(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 14 AND 15).
RX   PubMed=1313574; DOI=10.1073/pnas.89.7.2960;
RA   Katoh M., Hattori Y., Sasaki H., Tanaka M., Sugano K., Yazaki Y.,
RA   Sugimura T., Terada M.;
RT   "K-sam gene encodes secreted as well as transmembrane receptor
RT   tyrosine kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:2960-2964(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), DOMAIN, AND SUBUNIT.
RC   TISSUE=Placenta;
RX   PubMed=1400433;
RA   Dell K.R., Williams L.T.;
RT   "A novel form of fibroblast growth factor receptor 2. Alternative
RT   splicing of the third immunoglobulin-like domain confers ligand
RT   binding specificity.";
RL   J. Biol. Chem. 267:21225-21229(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3 AND 19), SUBUNIT, DOMAIN, AND
RP   VARIANT ARG-613.
RC   TISSUE=Mammary gland;
RX   PubMed=1309608; DOI=10.1073/pnas.89.1.246;
RA   Miki T., Bottaro D.P., Fleming T.P., Smith C.L., Burgess W.H.,
RA   Chan A.M.-L., Aaronson S.A.;
RT   "Determination of ligand-binding specificity by alternative splicing:
RT   two distinct growth factor receptors encoded by a single gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:246-250(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 19).
RC   TISSUE=Cornea, and Mammary gland;
RX   PubMed=7866434;
RA   Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M.,
RA   Shay J.W.;
RT   "Hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and
RT   their receptors in human breast cells and tissues: alternative
RT   receptors.";
RL   Cell. Mol. Biol. Res. 40:337-350(1994).
RN   [9]
RP   ERRATUM.
RA   Wilson S.E., Weng J., Chwang E.L., Gollahon L., Leitch A.M.,
RA   Shay J.W.;
RL   Cell. Mol. Biol. Res. 40:707-707(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT CS SER-342.
RC   TISSUE=Blood;
RA   Steinberger D., Mueller U.;
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 7; 9; 10; 11; 12 AND 13), AND
RP   VARIANT ARG-613.
RX   PubMed=10626794;
RA   Ueda T., Sasaki H., Kuwahara Y., Nezu M., Shibuya T., Sakamoto H.,
RA   Ishii H., Yanagihara K., Mafune K., Makuuchi M., Terada M.;
RT   "Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short
RT   homology-mediated recombination, generating preferential expression of
RT   specific messenger RNAs.";
RL   Cancer Res. 59:6080-6086(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 5; 6; 8; 14 AND 18).
RX   PubMed=11856867;
RA   Ingersoll R.G., Paznekas W.A., Tran A.K., Scott A.F., Jiang G.,
RA   Jabs E.W.;
RT   "Fibroblast growth factor receptor 2 (FGFR2): genomic sequence and
RT   variations.";
RL   Cytogenet. Cell Genet. 94:121-126(2001).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3).
RA   Lind D.L., Cox D.R.;
RT   "Sequence and polymorphisms in fibroblast growth factor receptor 2
RT   (FGFR2) gene in humans.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 23).
RA   Jang J.;
RT   "Identification of a novel variant of FGFR2.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PRO-6 AND THR-186.
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 21).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 20).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 314-427.
RX   PubMed=10712195; DOI=10.1086/302831;
RA   Glaser R.L., Jiang W., Boyadjiev S.A., Tran A.K., Zachary A.A.,
RA   Van Maldergem L., Johnson D., Walsh S., Oldridge M., Wall S.A.,
RA   Wilkie A.O.M., Jabs E.W.;
RT   "Paternal origin of FGFR2 mutations in sporadic cases of Crouzon
RT   syndrome and Pfeiffer syndrome.";
RL   Am. J. Hum. Genet. 66:768-777(2000).
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-209; 212-767 AND 771-821
RP   (ISOFORMS 5; 14 AND 18).
RX   PubMed=10196476; DOI=10.1016/S0378-1119(99)00047-5;
RA   Zhang Y., Gorry M.C., Post J.C., Ehrlich G.D.;
RT   "Genomic organization of the human fibroblast growth factor receptor 2
RT   (FGFR2) gene and comparative analysis of the human FGFR gene family.";
RL   Gene 230:69-79(1999).
RN   [21]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 249-313, AND VARIANTS APRS
RP   TRP-252 AND ARG-253.
RX   PubMed=7668257;
RA   Park W.-J., Theda C., Maestri N.E., Meyers G.A., Fryburg J.S.,
RA   Dufresne C., Cohen M.M. Jr., Jabs E.W.;
RT   "Analysis of phenotypic features and FGFR2 mutations in Apert
RT   syndrome.";
RL   Am. J. Hum. Genet. 57:321-328(1995).
RN   [22]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-259.
RX   PubMed=8676562;
RA   Wada C., Ishigaki M., Toyo-oka Y., Yamabe H., Ohnuki Y., Takada F.,
RA   Yamazaki Y., Ohtani H.;
RT   "Nucleotide sequences at intron 6 and exon 7 junction of fibroblast
RT   growth factor receptor 2 and rapid mutational analysis in Apert
RT   syndrome.";
RL   Rinsho Byori 44:435-438(1996).
RN   [23]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 251-318.
RX   PubMed=8673103; DOI=10.1038/ng0596-48;
RA   Moloney D.M., Slaney S.F., Oldridge M., Wall S.A., Sahlin P.,
RA   Stenman G., Wilkie A.O.M.;
RT   "Exclusive paternal origin of new mutations in Apert syndrome.";
RL   Nat. Genet. 13:48-53(1996).
RN   [24]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 263-361, AND VARIANTS CS PRO-289;
RP   ARG-338; SER-342; TYR-342; GLY-344 AND CYS-354.
RX   PubMed=7581378; DOI=10.1093/hmg/4.8.1387;
RA   Gorry M.C., Preston R.A., White G.J., Zhang Y., Singhal V.K.,
RA   Losken H.W., Parker M.G., Nwokoro N.A., Post J.C., Ehrlich G.D.;
RT   "Crouzon syndrome: mutations in two spliceoforms of FGFR2 and a common
RT   point mutation shared with Jackson-Weiss syndrome.";
RL   Hum. Mol. Genet. 4:1387-1390(1995).
RN   [25]
RP   FUNCTION (ISOFORM 3), SUBUNIT, AND DOMAIN.
RX   PubMed=8961926; DOI=10.1021/bi961942c;
RA   Gray T.E., Eisenstein M., Yayon A., Givol D.;
RT   "Asparagine-344 is a key residue for ligand binding in keratinocyte
RT   growth factor receptor.";
RL   Biochemistry 35:15640-15645(1996).
RN   [26]
RP   INTERACTION WITH FGF1; FGF2; FGF3; FGF4; FGF6; FGF7 AND FGF9, AND
RP   FUNCTION IN CELL PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A.,
RA   Coulier F., Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [27]
RP   INVOLVEMENT IN SCS, AND VARIANT SCS 269-VAL-VAL-270 DEL.
RX   PubMed=9585583; DOI=10.1086/301855;
RA   Paznekas W.A., Cunningham M.L., Howard T.D., Korf B.R., Lipson M.H.,
RA   Grix A.W., Feingold M., Goldberg R., Borochowitz Z., Aleck K.,
RA   Mulliken J., Yin M., Jabs E.W.;
RT   "Genetic heterogeneity of Saethre-Chotzen syndrome, due to TWIST and
RT   FGFR mutations.";
RL   Am. J. Hum. Genet. 62:1370-1380(1998).
RN   [28]
RP   FUNCTION IN PHOSPHORYLATION OF PAK4; REGULATION OF CELL PROLIFERATION
RP   AND APOPTOSIS, AND INTERACTION WITH GRB2 AND PAK4.
RX   PubMed=12529371; DOI=10.1074/jbc.M205875200;
RA   Lu Y., Pan Z.-Z., Devaux Y., Ray P.;
RT   "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte
RT   growth factor receptor and participates in keratinocyte growth factor-
RT   mediated inhibition of oxidant-induced cell death.";
RL   J. Biol. Chem. 278:10374-10380(2003).
RN   [29]
RP   FUNCTION IN OSTEOBLAST DIFFERENTIATION AND IN PHOSPHORYLATION OF CBL,
RP   INTERACTION WITH CBL, UBIQUITINATION, AND CHARACTERIZATION OF VARIANT
RP   APRS TRP-252.
RX   PubMed=15190072; DOI=10.1074/jbc.M402469200;
RA   Kaabeche K., Lemonnier J., Le Mee S., Caverzasio J., Marie P.J.;
RT   "Cbl-mediated degradation of Lyn and Fyn induced by constitutive
RT   fibroblast growth factor receptor-2 activation supports osteoblast
RT   differentiation.";
RL   J. Biol. Chem. 279:36259-36267(2004).
RN   [30]
RP   FUNCTION IN CELL PROLIFERATION AND ACTIVATION OF SIGNALING PATHWAYS,
RP   MUTAGENESIS OF TYR-769, PHOSPHORYLATION AT TYR-769, AND INTERACTION
RP   WITH PLCG1.
RX   PubMed=15629145; DOI=10.1016/j.bbrc.2004.12.031;
RA   Ceridono M., Belleudi F., Ceccarelli S., Torrisi M.R.;
RT   "Tyrosine 769 of the keratinocyte growth factor receptor is required
RT   for receptor signaling but not endocytosis.";
RL   Biochem. Biophys. Res. Commun. 327:523-532(2005).
RN   [31]
RP   INTERACTION WITH FGF1; FGF7; FGF8; FGF9; FGF10; FGF19; FGF21; FGF22
RP   AND FGF23, AND FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.M601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M.,
RA   Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The
RT   complete mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF PLCG1 (ISOFORM 1), CATALYTIC ACTIVITY,
RP   AUTOPHOSPHORYLATION, GLYCOSYLATION, INTERACTION WITH PLCG1,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF ASN-265 AND 656-TYR-TYR-657,
RP   UBIQUITINATION, AND CHARACTERIZATION OF VARIANT PS PHE-278.
RX   PubMed=16844695; DOI=10.1074/jbc.M600448200;
RA   Hatch N.E., Hudson M., Seto M.L., Cunningham M.L., Bothwell M.;
RT   "Intracellular retention, degradation, and signaling of glycosylation-
RT   deficient FGFR2 and craniosynostosis syndrome-associated FGFR2C278F.";
RL   J. Biol. Chem. 281:27292-27305(2006).
RN   [33]
RP   INTERACTION WITH FGF19; FGF21 AND KLB, AND FUNCTION IN PHOSPHORYLATION
RP   OF FRS2 AND ACTIVATION OF MAP KINASES.
RX   PubMed=17623664; DOI=10.1074/jbc.M704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R.,
RA   Eliseenkova A.V., Mohammadi M., Rosenblatt K.P., Kliewer S.A.,
RA   Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and
RT   FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [34]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, SUBCELLULAR
RP   LOCATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at
RT   the Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [35]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18374639; DOI=10.1016/j.bone.2008.02.009;
RA   Dufour C., Guenou H., Kaabeche K., Bouvard D., Sanjay A., Marie P.J.;
RT   "FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt
RT   signaling and osteoblast survival.";
RL   Bone 42:1032-1039(2008).
RN   [36]
RP   FUNCTION AS FGF7 RECEPTOR AND IN PHOSPHORYLATION OF PLCG1 AND FRS2,
RP   CATALYTIC ACTIVITY, PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588;
RP   TYR-656 AND TYR-657, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19410646; DOI=10.1016/j.cellsig.2009.04.004;
RA   Luo Y., Yang C., Jin C., Xie R., Wang F., McKeehan W.L.;
RT   "Novel phosphotyrosine targets of FGFR2IIIb signaling.";
RL   Cell. Signal. 21:1370-1378(2009).
RN   [37]
RP   FUNCTION IN FIBROBLAST PROLIFERATION; ACTIVATION OF MAP KINASES AND
RP   PHOSPHORYLATION OF PLCG1 AND FRS2, INTERACTION WITH PLCG1 AND FRS2,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-769.
RX   PubMed=19103595; DOI=10.1074/jbc.M803998200;
RA   Cha J.Y., Maddileti S., Mitin N., Harden T.K., Der C.J.;
RT   "Aberrant receptor internalization and enhanced FRS2-dependent
RT   signaling contribute to the transforming activity of the fibroblast
RT   growth factor receptor 2 IIIb C3 isoform.";
RL   J. Biol. Chem. 284:6227-6240(2009).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [39]
RP   FUNCTION, AND UBIQUITINATION.
RX   PubMed=21596750; DOI=10.1074/jbc.M110.197525;
RA   Severe N., Miraoui H., Marie P.J.;
RT   "The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic
RT   differentiation in human mesenchymal stromal cells in part by
RT   decreased Cbl-mediated platelet-derived growth factor receptor alpha
RT   and fibroblast growth factor receptor 2 ubiquitination.";
RL   J. Biol. Chem. 286:24443-24450(2011).
RN   [40]
RP   REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, AND SIGNALING.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [41]
RP   REVIEW ON LIGAND SPECIFICITY, ALTERNATIVE SPLICING, SIGNALING, AND
RP   ROLE IN DISEASE.
RX   PubMed=19387476; DOI=10.1038/jid.2009.97;
RA   Katoh M.;
RT   "FGFR2 abnormalities underlie a spectrum of bone, skin, and cancer
RT   pathologies.";
RL   J. Invest. Dermatol. 129:1861-1867(2009).
RN   [42]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-780, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 147-366 IN COMPLEX WITH FGF2.
RX   PubMed=10830168; DOI=10.1016/S0092-8674(00)80851-X;
RA   Plotnikov A.N., Hubbard S.R., Schlessinger J., Mohammadi M.;
RT   "Crystal structures of two FGF-FGFR complexes reveal the determinants
RT   of ligand-receptor specificity.";
RL   Cell 101:413-424(2000).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 148-366 IN COMPLEX WITH FGF1
RP   AND HEPARIN, AND INTERACTION WITH FGF1 AND HEPARIN.
RX   PubMed=11069186; DOI=10.1038/35039551;
RA   Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L.;
RT   "Crystal structure of fibroblast growth factor receptor ectodomain
RT   bound to ligand and heparin.";
RL   Nature 407:1029-1034(2000).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 147-362 IN COMPLEX WITH FGF1.
RX   PubMed=10618369; DOI=10.1073/pnas.97.1.49;
RA   Stauber D.J., DiGabriele A.D., Hendrickson W.A.;
RT   "Structural interactions of fibroblast growth factor receptor with its
RT   ligands.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:49-54(2000).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 147-366 OF VARIANTS APRS
RP   TRP-252 AND ARG-253 IN COMPLEX WITH FGF2.
RX   PubMed=11390973; DOI=10.1073/pnas.121183798;
RA   Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M.,
RA   Mohammadi M.;
RT   "Structural basis for fibroblast growth factor receptor 2 activation
RT   in Apert syndrome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:7182-7187(2001).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 140-371 IN COMPLEX WITH
RP   FGF10.
RX   PubMed=12591959; DOI=10.1073/pnas.0436500100;
RA   Yeh B.K., Igarashi M., Eliseenkova A.V., Plotnikov A.N., Sher I.,
RA   Ron D., Aaronson S.A., Mohammadi M.;
RT   "Structural basis by which alternative splicing confers specificity in
RT   fibroblast growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:2266-2271(2003).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 149-368 IN COMPLEX WITH
RP   FGF8, FUNCTION AS FGF8 RECEPTOR, INTERACTION WITH FGF8, AND DISULFIDE
RP   BONDS.
RX   PubMed=16384934; DOI=10.1101/gad.1365406;
RA   Olsen S.K., Li J.Y.H., Bromleigh C., Eliseenkova A.V., Ibrahimi O.A.,
RA   Lao Z., Zhang F., Linhardt R.J., Joyner A.L., Mohammadi M.;
RT   "Structural basis by which alternative splicing modulates the
RT   organizer activity of FGF8 in the brain.";
RL   Genes Dev. 20:185-198(2006).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP
RP   ANALOG; PEPTIDE SUBSTRATE AND MAGNESIUM, ACTIVITY REGULATION,
RP   PHOSPHORYLATION AT TYR-586; TYR-656 AND TYR-657, MUTAGENESIS OF
RP   ASN-549 AND GLU-565, CHARACTERIZATION OF VARIANT FSPC GLU-526,
RP   CHARACTERIZATION OF VARIANT CS HIS-549, CHARACTERIZATION OF VARIANTS
RP   PS GLY-565 AND ARG-641, AND CHARACTERIZATION OF VARIANT
RP   CRANIOSYNOSTOSIS ASN-659.
RX   PubMed=17803937; DOI=10.1016/j.molcel.2007.06.028;
RA   Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A.,
RA   Miller W.T., Mohammadi M.;
RT   "A molecular brake in the kinase hinge region regulates the activity
RT   of receptor tyrosine kinases.";
RL   Mol. Cell 27:717-730(2007).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 458-766 OF VARIANT LADDS
RP   THR-628 IN COMPLEX WITH ATP ANALOG, CATALYTIC ACTIVITY, SUBUNIT, AND
RP   AUTOPHOSPHORYLATION.
RX   PubMed=18056630; DOI=10.1073/pnas.0709905104;
RA   Lew E.D., Bae J.H., Rohmann E., Wollnik B., Schlessinger J.;
RT   "Structural basis for reduced FGFR2 activity in LADD syndrome:
RT   Implications for FGFR autoinhibition and activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:19802-19807(2007).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 458-778 IN COMPLEX WITH ATP,
RP   ACTIVE SITE, IDENTIFICATION BY MASS SPECTROMETRY, AUTOPHOSPHORYLATION,
RP   AND PHOSPHORYLATION AT TYR-466; TYR-586; TYR-588; TYR-656; TYR-657 AND
RP   TYR-769.
RX   PubMed=19060208; DOI=10.1073/pnas.0807752105;
RA   Chen H., Xu C.F., Ma J., Eliseenkova A.V., Li W., Pollock P.M.,
RA   Pitteloud N., Miller W.T., Neubert T.A., Mohammadi M.;
RT   "A crystallographic snapshot of tyrosine trans-phosphorylation in
RT   action.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:19660-19665(2008).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 458-768 IN COMPLEX WITH
RP   INHIBITOR, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND ACTIVITY
RP   REGULATION.
RX   PubMed=21454610; DOI=10.1074/jbc.M110.213736;
RA   Eathiraj S., Palma R., Hirschi M., Volckova E., Nakuci E., Castro J.,
RA   Chen C.R., Chan T.C., France D.S., Ashwell M.A.;
RT   "A novel mode of protein kinase inhibition exploiting hydrophobic
RT   motifs of autoinhibited kinases: discovery of ATP-independent
RT   inhibitors of fibroblast growth factor receptor.";
RL   J. Biol. Chem. 286:20677-20687(2011).
RN   [54]
RP   VARIANTS CS HIS-340; ARG-342; SER-342; TYR-342 AND CYS-354.
RX   PubMed=7987400; DOI=10.1038/ng0994-98;
RA   Reardon W., Winter R.M., Rutland P., Pulleyn L.J., Jones B.M.,
RA   Malcolm S.;
RT   "Mutations in the fibroblast growth factor receptor 2 gene cause
RT   Crouzon syndrome.";
RL   Nat. Genet. 8:98-103(1994).
RN   [55]
RP   VARIANTS CS CYS-328 AND CYS-347, AND VARIANT JWS GLY-344.
RX   PubMed=7874170; DOI=10.1038/ng1194-275;
RA   Jabs E.W., Li X., Scott A.F., Meyers G.A., Chen W., Eccles M., Mao J.,
RA   Charnas L.R., Jackson C.E., Jaye M.;
RT   "Jackson-Weiss and Crouzon syndromes are allelic with mutations in
RT   fibroblast growth factor receptor 2.";
RL   Nat. Genet. 8:275-279(1994).
RN   [56]
RP   VARIANTS CS.
RX   PubMed=7655462; DOI=10.1093/hmg/4.6.1077;
RA   Oldridge M., Wilkie A.O.M., Slaney S.F., Poole M.D., Pulleyn L.J.,
RA   Rutland P., Hockley A.D., Wake M.J.C., Goldin J.H., Winter R.M.,
RA   Reardon W., Malcolm S.;
RT   "Mutations in the third immunoglobulin domain of the fibroblast growth
RT   factor receptor-2 gene in Crouzon syndrome.";
RL   Hum. Mol. Genet. 4:1077-1082(1995).
RN   [57]
RP   VARIANTS CS GLY-290; TRP-342 AND CYS-354, AND VARIANT JWS ARG-342.
RX   PubMed=8528214; DOI=10.1093/hmg/4.7.1229;
RA   Park W.-J., Meyers G.A., Li X., Theda C., Day D., Orlow S.J.,
RA   Jones M.C., Jabs E.W.;
RT   "Novel FGFR2 mutations in Crouzon and Jackson-Weiss syndromes show
RT   allelic heterogeneity and phenotypic variability.";
RL   Hum. Mol. Genet. 4:1229-1233(1995).
RN   [58]
RP   VARIANT PS ALA-321.
RX   PubMed=7719333; DOI=10.1038/ng0295-108;
RA   Lajeunie E., Wei M.H., Bonaventure J., Munnich A., le Merrer M.,
RA   Renier D.;
RT   "FGFR2 mutations in Pfeiffer syndrome.";
RL   Nat. Genet. 9:108-108(1995).
RN   [59]
RP   VARIANTS APRS TRP-252 AND ARG-253.
RX   PubMed=7719344; DOI=10.1038/ng0295-165;
RA   Wilkie A.O.M., Slaney S.F., Oldridge M., Poole M.D., Ashworth G.J.,
RA   Hockley A.D., Hayward R.D., David D.J., Pulleyn L.J., Rutland P.,
RA   Malcolm S., Winter R.M., Reardon W.;
RT   "Apert syndrome results from localized mutations of FGFR2 and is
RT   allelic with Crouzon syndrome.";
RL   Nat. Genet. 9:165-172(1995).
RN   [60]
RP   VARIANTS PS PRO-341; ARG-342 AND TYR-342.
RX   PubMed=7719345; DOI=10.1038/ng0295-173;
RA   Rutland P., Pulleyn L.J., Reardon W., Baraister M., Hayward R.,
RA   Jones B.M., Malcolm S., Winter R.M., Oldridge M., Slaney S.F.,
RA   Poole M.D., Wilkie A.O.M.;
RT   "Identical mutations in the FGFR2 gene cause both Pfeiffer and Crouzon
RT   syndrome phenotypes.";
RL   Nat. Genet. 9:173-176(1995).
RN   [61]
RP   VARIANTS CS GLY-268 INS; PHE-342 AND TYR-342, VARIANTS PS PHE-278;
RP   ARG-342; SER-342; PRO-344 AND PHE-359, AND VARIANT JWS PRO-289.
RX   PubMed=8644708;
RA   Meyers G.A., Day D., Goldberg R., Daentl D.L., Przylepa K.A.,
RA   Abrams L.J., Graham J.M. Jr., Feingold M., Moeschler J.B.,
RA   Rawnsley E., Scott A.F., Jabs E.W.;
RT   "FGFR2 exon IIIa and IIIc mutations in Crouzon, Jackson-Weiss, and
RT   Pfeiffer syndromes: evidence for missense changes, insertions, and a
RT   deletion due to alternative RNA splicing.";
RL   Am. J. Hum. Genet. 58:491-498(1996).
RN   [62]
RP   VARIANTS CS CYS-105; GLU-338; CYS-351 AND ARG-384.
RX   PubMed=8946174;
RA   Pulleyn L.J., Reardon W., Wilkes D., Rutland P., Jones B.M.,
RA   Hayward R., Hall C.M., Brueton L., Chun N., Lammer E., Malcolm S.,
RA   Winter R.M.;
RT   "Spectrum of craniosynostosis phenotypes associated with novel
RT   mutations at the fibroblast growth factor receptor 2 locus.";
RL   Eur. J. Hum. Genet. 4:283-291(1996).
RN   [63]
RP   VARIANTS CS ILE-331; ASN-ALA-337 INS AND 356-TRP--THR-358 DEL.
RX   PubMed=8956050;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:4<386::AID-HUMU18>3.3.CO;2-A;
RA   Steinberger D., Mulliken J.B., Mueller U.;
RT   "Crouzon syndrome: previously unrecognized deletion, duplication, and
RT   point mutation within FGFR2 gene.";
RL   Hum. Mutat. 8:386-390(1996).
RN   [64]
RP   VARIANTS BSTVS CYS-372 AND CYS-375.
RX   PubMed=8696350; DOI=10.1038/ng0896-492;
RA   Przylepa K.A., Paznekas W.A., Zhang M., Golabi M., Bias W.,
RA   Bamshad M.J., Carey J.C., Hall B.D., Stevenson R., Orlow S.J.,
RA   Cohen M.M. Jr., Jabs E.W.;
RT   "Fibroblast growth factor receptor 2 mutations in Beare-Stevenson
RT   cutis gyrata syndrome.";
RL   Nat. Genet. 13:492-494(1996).
RN   [65]
RP   VARIANT PS CYS-290.
RX   PubMed=9150725; DOI=10.1007/s004390050413;
RA   Tartaglia M., Valeri S., Velardi F., di Rocco C., Battaglia P.A.;
RT   "Trp290Cys mutation in exon IIIa of the fibroblast growth factor
RT   receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome.";
RL   Hum. Genet. 99:602-606(1997).
RN   [66]
RP   VARIANT JWS SER-342.
RX   PubMed=9385368; DOI=10.1007/s004390050584;
RA   Tartaglia M., Di Rocco C., Lajeunie E., Valeri S., Velardi F.,
RA   Battaglia P.A.;
RT   "Jackson-Weiss syndrome: identification of two novel FGFR2 missense
RT   mutations shared with Crouzon and Pfeiffer craniosynostotic
RT   disorders.";
RL   Hum. Genet. 101:47-50(1997).
RN   [67]
RP   VARIANT LEU-252, VARIANT APRS PHE-252, AND VARIANT PS 252-PHE-SER-253.
RX   PubMed=9002682; DOI=10.1093/hmg/6.1.137;
RA   Oldridge M., Lunt P.W., Zackai E.H., McDonald-Mcginn D.M., Muenke M.,
RA   Moloney D.M., Twigg S.R.F., Heath J.K., Howard T.D., Hoganson G.,
RA   Gagnon D.M., Jabs E.W., Wilkie A.O.M.;
RT   "Genotype-phenotype correlation for nucleotide substitutions in the
RT   IgII-IgIII linker of FGFR2.";
RL   Hum. Mol. Genet. 6:137-143(1997).
RN   [68]
RP   VARIANT CS GLU-292.
RX   PubMed=9152842; DOI=10.1136/jmg.34.5.420;
RA   Steinberger D., Collmann H., Schmalenberger B., Mueller U.;
RT   "A novel mutation (a886g) in exon 5 of FGFR2 in members of a family
RT   with Crouzon phenotype and plagiocephaly.";
RL   J. Med. Genet. 34:420-422(1997).
RN   [69]
RP   VARIANTS CS PHE-278; PRO-337; ARG-338; ARG-342; PHE-342 AND TYR-342,
RP   VARIANTS APRS TRP-252 AND ARG-253, AND VARIANT JWS PHE-278.
RX   PubMed=9677057;
RX   DOI=10.1002/(SICI)1096-8628(19980707)78:3<237::AID-AJMG5>3.3.CO;2-5;
RA   Passos-Bueno M.R., Sertie A.L., Richieri-Costa A., Alonso L.G.,
RA   Zatz M., Alonso N., Brunoni D., Ribeiro S.F.M.;
RT   "Description of a new mutation and characterization of FGFR1, FGFR2,
RT   and FGFR3 mutations among Brazilian patients with syndromic
RT   craniosynostoses.";
RL   Am. J. Med. Genet. 78:237-241(1998).
RN   [70]
RP   VARIANTS CS VAL-276 AND CYS-301, AND VARIANT CRANIOSYNOSTOSIS SER-314.
RX   PubMed=9521581; DOI=10.1007/s004390050668;
RA   Steinberger D., Vriend G., Mulliken J.B., Mueller U.;
RT   "The mutations in FGFR2-associated craniosynostoses are clustered in
RT   five structural elements of immunoglobulin-like domain III of the
RT   receptor.";
RL   Hum. Genet. 102:145-150(1998).
RN   [71]
RP   VARIANTS APRS TRP-252 AND ARG-253.
RX   PubMed=9452027;
RA   Tsai F.-J., Hwu W.-L., Lin S.-P., Chang J.-G., Wang T.-R., Tsai C.-H.;
RT   "Two common mutations 934C to G and 937C to G of fibroblast growth
RT   factor receptor 2 (FGFR2) gene in Chinese patients with Apert
RT   syndrome.";
RL   Hum. Mutat. Suppl. 1:S18-S19(1998).
RN   [72]
RP   VARIANT PS CYS-351.
RX   PubMed=9693549;
RA   Mathijssen I.M., Vaandrager J.M., Hoogeboom A.J.,
RA   Hesseling-Janssen A.L.W., van den Ouweland A.M.W.;
RT   "Pfeiffer's syndrome resulting from an S351C mutation in the
RT   fibroblast growth factor receptor-2 gene.";
RL   J. Craniofac. Surg. 9:207-209(1998).
RN   [73]
RP   VARIANT PS TRP-252.
RX   PubMed=9719378; DOI=10.1136/jmg.35.8.677;
RA   Passos-Bueno M.R., Richieri-Costa A., Sertie A.L., Kneppers A.;
RT   "Presence of the Apert canonical S252W FGFR2 mutation in a patient
RT   without severe syndactyly.";
RL   J. Med. Genet. 35:677-679(1998).
RN   [74]
RP   VARIANT CS SER-362.
RX   PubMed=10574673; DOI=10.1597/1545-1569(1999)036<0533:ANFGMI>2.3.CO;2;
RA   Everett E.T., Britto D.A., Ward R.E., Hartsfield J.K. Jr.;
RT   "A novel FGFR2 gene mutation in Crouzon syndrome associated with
RT   apparent nonpenetrance.";
RL   Cleft Palate Craniofac. J. 36:533-541(1999).
RN   [75]
RP   VARIANTS PS CYS-340 AND GLY-342.
RX   PubMed=10394936; DOI=10.1007/s004390050979;
RA   Cornejo-Roldan L.R., Roessler E., Muenke M.;
RT   "Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer
RT   syndrome.";
RL   Hum. Genet. 104:425-431(1999).
RN   [76]
RP   VARIANT PS ASP-273 DEL.
RX   PubMed=10945669; DOI=10.1034/j.1399-0004.2000.580116.x;
RA   Priolo M., Lerone M., Baffico M., Baldi M., Ravazzolo R., Cama A.,
RA   Capra V., Silengo M.;
RT   "Pfeiffer syndrome type 2 associated with a single amino acid deletion
RT   in the FGFR2 gene.";
RL   Clin. Genet. 58:81-83(2000).
RN   [77]
RP   VARIANTS CS/PS ARG-342 AND TYR-342, VARIANTS CS LEU-263; VAL-276;
RP   PHE-278; TYR-278; SER-288; PRO-289; PRO-341; TRP-342; CYS-354; TYR-354
RP   AND PHE-359, AND VARIANT PS SER-342.
RX   PubMed=11173845;
RA   Kress W., Collmann H., Buesse M., Halliger-Keller B., Mueller C.R.;
RT   "Clustering of FGFR2 gene mutations in patients with Pfeiffer and
RT   Crouzon syndromes (FGFR2-associated craniosynostoses).";
RL   Cytogenet. Cell Genet. 91:134-137(2000).
RN   [78]
RP   VARIANT SER-315.
RX   PubMed=10951518; DOI=10.1038/sj.ejhg.5200499;
RA   Johnson D., Wall S.A., Mann S., Wilkie A.O.M.;
RT   "A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction
RT   leading to craniosynostosis?";
RL   Eur. J. Hum. Genet. 8:571-577(2000).
RN   [79]
RP   VARIANTS ABS2 ARG-342; SER-342 AND CYS-351.
RX   PubMed=10633130; DOI=10.1136/jmg.37.1.26;
RA   Reardon W., Smith A., Honour J.W., Hindmarsh P., Das D., Rumsby G.,
RA   Nelson I., Malcolm S., Ades L., Sillence D., Kumar D.,
RA   DeLozier-Blanchet C., McKee S., Kelly T., McKeehan W.L., Baraitser M.,
RA   Winter R.M.;
RT   "Evidence for digenic inheritance in some cases of Antley-Bixler
RT   syndrome?";
RL   J. Med. Genet. 37:26-32(2000).
RN   [80]
RP   VARIANTS CS CYS-281; PRO-289; ARG-342 AND TYR-342.
RX   PubMed=11380921; DOI=10.1046/j.1442-200x.2001.01392.x;
RA   Tsai F.-J., Yang C.-F., Wu J.-Y., Tsai C.-H., Lee C.-C.;
RT   "Mutation analysis of Crouzon syndrome and identification of one novel
RT   mutation in Taiwanese patients.";
RL   Pediatr. Int. 43:263-266(2001).
RN   [81]
RP   VARIANTS CS CYS-105; PRO-267; VAL-276; CYS-281; PRO-289; ARG-338;
RP   HIS-340; PHE-342; TRP-342; CYS-347; CYS-354; HIS-549 AND GLY-678,
RP   VARIANTS PS PHE-172; 252-PHE-SER-253; CYS-290; CYS-340; PRO-341;
RP   ARG-342; SER-342; CYS-375; GLY-565; ARG-641 AND GLU-663, VARIANTS APRS
RP   TRP-252 AND ARG-253, VARIANTS CS/PS PHE-278 AND TYR-342, VARIANT
RP   CRANIOSYNOSTOSIS ASN-659, AND VARIANTS THR-186 AND SER-315.
RX   PubMed=11781872; DOI=10.1086/338758;
RA   Kan S.-H., Elanko N., Johnson D., Cornejo-Roldan L.R., Cook J.,
RA   Reich E.W., Tomkins S., Verloes A., Twigg S.R.F., Rannan-Eliya S.,
RA   McDonald-McGinn D.M., Zackai E.H., Wall S.A., Muenke M.,
RA   Wilkie A.O.M.;
RT   "Genomic screening of fibroblast growth-factor receptor 2 reveals a
RT   wide spectrum of mutations in patients with syndromic
RT   craniosynostosis.";
RL   Am. J. Hum. Genet. 70:472-486(2002).
RN   [82]
RP   VARIANT BSTVS CYS-375.
RX   PubMed=12000365; DOI=10.1034/j.1399-0004.2002.610309.x;
RA   Wang T.-J., Huang C.-B., Tsai F.-J., Wu J.-Y., Lai R.-B., Hsiao M.;
RT   "Mutation in the FGFR2 gene in a Taiwanese patient with Beare-
RT   Stevenson cutis gyrata syndrome.";
RL   Clin. Genet. 61:218-221(2002).
RN   [83]
RP   VARIANT FSPC GLU-526.
RX   PubMed=16061565; DOI=10.1136/jmg.2004.027888;
RA   McGillivray G., Savarirayan R., Cox T.C., Stojkoski C., McNeil R.,
RA   Bankier A., Bateman J.F., Roscioli T., Gardner R.J.M., Lamande S.R.;
RT   "Familial scaphocephaly syndrome caused by a novel mutation in the
RT   FGFR2 tyrosine kinase domain.";
RL   J. Med. Genet. 42:656-662(2005).
RN   [84]
RP   VARIANTS LADDS THR-628; THR-648 AND 649-ARG-ASP-650 DELINS SER.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G.,
RA   Lew E.D., Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M.,
RA   Leroy J.G., Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J.,
RA   Yueksel-Apak M., Nuernberg P., Kubisch C., Schlessinger J.,
RA   van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD
RT   syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [85]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-203.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [86]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-57; THR-186; CYS-203; VAL-272;
RP   ASN-283; CYS-290 AND THR-612.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [87]
RP   VARIANTS BBDS ASP-381 AND ARG-391, AND CHARACTERIZATION OF VARIANT
RP   BBDS ARG-391.
RX   PubMed=22387015; DOI=10.1016/j.ajhg.2012.02.005;
RA   Merrill A.E., Sarukhanov A., Krejci P., Idoni B., Camacho N.,
RA   Estrada K.D., Lyons K.M., Deixler H., Robinson H., Chitayat D.,
RA   Curry C.J., Lachman R.S., Wilcox W.R., Krakow D.;
RT   "Bent bone dysplasia-FGFR2 type, a distinct skeletal disorder, has
RT   deficient canonical FGF signaling.";
RL   Am. J. Hum. Genet. 90:550-557(2012).
RN   [88]
RP   VARIANT LEU-57.
RX   PubMed=26429889; DOI=10.1136/jmedgenet-2015-103336;
RA   Perles Z., Moon S., Ta-Shma A., Yaacov B., Francescatto L.,
RA   Edvardson S., Rein A.J., Elpeleg O., Katsanis N.;
RT   "A human laterality disorder caused by a homozygous deleterious
RT   mutation in MMP21.";
RL   J. Med. Genet. 52:840-847(2015).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=23;
CC       Name=1; Synonyms=BEK, FGFR2IIIc;
CC         IsoId=P21802-1; Sequence=External;
CC       Name=2; Synonyms=Short;
CC         IsoId=P21802-2; Sequence=VSP_002978;
CC       Name=3; Synonyms=BFR-1, FGFR2IIIb, KGFR;
CC         IsoId=P21802-3; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972;
CC       Name=4; Synonyms=K-sam;
CC         IsoId=P21802-4; Sequence=VSP_002964, VSP_002969, VSP_002970,
CC                                  VSP_002971, VSP_002972, VSP_002975,
CC                                  VSP_002976;
CC       Name=5; Synonyms=K-sam-I, BEK, IgIIIc;
CC         IsoId=P21802-5; Sequence=VSP_002975;
CC       Name=6; Synonyms=K-sam-IIC2;
CC         IsoId=P21802-6; Sequence=VSP_002975, VSP_002984;
CC       Name=7; Synonyms=K-sam-IIO2;
CC         IsoId=P21802-7; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972, VSP_002979;
CC       Name=8; Synonyms=K-sam-IIC3;
CC         IsoId=P21802-8; Sequence=VSP_002975, VSP_002978;
CC       Name=9; Synonyms=K-sam-IIH1;
CC         IsoId=P21802-9; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                  VSP_002972, VSP_002980;
CC       Name=10; Synonyms=K-sam-IIH2;
CC         IsoId=P21802-10; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002981;
CC       Name=11; Synonyms=K-sam-IIH3, K-sam-IIO4;
CC         IsoId=P21802-11; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002982;
CC       Name=12; Synonyms=K-sam-IIO1;
CC         IsoId=P21802-12; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002983;
CC       Name=13; Synonyms=K-sam-IIO3;
CC         IsoId=P21802-13; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002977;
CC       Name=14; Synonyms=K-sam-IV, Soluble KGFR;
CC         IsoId=P21802-14; Sequence=VSP_002965, VSP_002966;
CC       Name=15; Synonyms=K-sam-III;
CC         IsoId=P21802-15; Sequence=VSP_002968;
CC       Name=16; Synonyms=TK14;
CC         IsoId=P21802-16; Sequence=VSP_002967, VSP_002975;
CC         Note=Ref.2 (AAA61188) sequence is in conflict in position:
CC         315:T->L. {ECO:0000305};
CC       Name=17;
CC         IsoId=P21802-17; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002978;
CC       Name=18; Synonyms=K-sam-IIC1, KGFR, IgIIIb;
CC         IsoId=P21802-18; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002975;
CC       Name=19; Synonyms=Soluble KGFR;
CC         IsoId=P21802-19; Sequence=VSP_002969, VSP_002970, VSP_002971,
CC                                   VSP_002972, VSP_002973, VSP_002974;
CC       Name=20;
CC         IsoId=P21802-20; Sequence=VSP_019608, VSP_019609;
CC       Name=21;
CC         IsoId=P21802-21; Sequence=VSP_002964, VSP_041915;
CC       Name=22;
CC         IsoId=P21802-22; Sequence=VSP_002964, VSP_002969, VSP_002970,
CC                                   VSP_002971, VSP_002972, VSP_002978;
CC       Name=23;
CC         IsoId=P21802-23; Sequence=VSP_041914;
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   ProteomicsDB; 53916; -. [P21802-2]
PE   1: Evidence at protein level;
SQ   SEQUENCE   768 AA;  86130 MW;  8D4734CBEA8E8C8F CRC64;
     MVSWGRFICL VVVTMATLSL ARPSFSLVED TTLEPEEPPT KYQISQPEVY VAAPGESLEV
     RCLLKDAAVI SWTKDGVHLG PNNRTVLIGE YLQIKGATPR DSGLYACTAS RTVDSETWYF
     MVNVTDAISS GDDEDDTDGA EDFVSENSNN KRAPYWTNTE KMEKRLHAVP AANTVKFRCP
     AGGNPMPTMR WLKNGKEFKQ EHRIGGYKVR NQHWSLIMES VVPSDKGNYT CVVENEYGSI
     NHTYHLDVVE RSPHRPILQA GLPANASTVV GGDVEFVCKV YSDAQPHIQW IKHVEKNGSK
     YGPDGLPYLK VLKAAGVNTT DKEIEVLYIR NVTFEDAGEY TCLAGNSIGI SFHSAWLTVL
     PAPGREKEIT ASPDYLEIAI YCIGVFLIAC MVVTVILCRM KNTTKKPDFS SQPAVHKLTK
     RIPLRRQVTV SAESSSSMNS NTPLVRITTR LSSTADTPML AGVSEYELPE DPKWEFPRDK
     LTLGKPLGEG CFGQVVMAEA VGIDKDKPKE AVTVAVKMLK DDATEKDLSD LVSEMEMMKM
     IGKHKNIINL LGACTQDGPL YVIVEYASKG NLREYLRARR PPGMEYSYDI NRVPEEQMTF
     KDLVSCTYQL ARGMEYLASQ KCIHRDLAAR NVLVTENNVM KIADFGLARD INNIDYYKKT
     TNGRLPVKWM APEALFDRVY THQSDVWSFG VLMWEIFTLG GSPYPGIPVE ELFKLLKEGH
     RMDKPANCTN ELYMMMRDCW HAVPSQRPTF KQLVEDLDRI LTLTTNEI
//
